Shopping Cart

Your shopping cart is currently empty

L-Arginine

Name: L-Arginine
Brand: TargetMol
SKU: T3S0364
Price: 31 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: L-Arg, (S)-(+)-Arginine) Copy Product Info

🥰Excellent

Synonyms: L-Arg, (S)-(+)-Arginine

Catalog No. T3S0364 Copy Product Info

Purity: 99.92%

🥰Excellent

L-Arginine (L-Arg) is a substrate for endothelial nitric oxide synthase (eNOS), participating in protein synthesis, polyamine production, and cellular signaling regulation. L-Arginine is transported into vascular smooth muscle cells via the cationic amino acid transporter family and metabolized into nitric oxide, polyamines, or L-proline. L-Arginine is an effective vasodilator and can be used to induce experimental acute pancreatitis.

Cas No. 74-79-3

Pack Size	Price	USA Stock	Global Stock	Quantity
1 g	$31	In Stock	In Stock
5 g	$40	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.92%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

L-Arginine AI Summary

L-Arginine exhibits a diverse range of bioactivities significant for various biochemical and biomedical research areas. It is a potent inhibitor of nitric oxide synthase (NOS) with Km values of 2200.0 nM for inducible NOS, 900.0 nM for endothelial NOS, and 1600.0 nM for neuronal NOS, suggesting the potential for modulation of nitric oxide production. It shows bioactivity in improving in vivo blood glucose levels in insulin-resistant KKAy mice, evidencing its therapeutic potential in metabolic disorders. The compound demonstrates inhibitory action against hairpin ribozyme cleavage, NO-releasing ability, interaction with tryptase, and formation of advanced glycation end products. It exhibits antiviral activity against feline herpes virus and feline coronavirus in cat CRFK cells, with EC50 values of 1.6 µg/mL and 2.6 µg/mL respectively. Additionally, it shows protective effects in Wistar rat liver against ischemia-reperfusion injury and has an antinociceptive effect in mice. L-Arginine has activity related to the regulation of defensive enzymes in plants, upregulating beta-1,3-glucanase and chitinase to mitigate tomato fruit gray mold disease. It demonstrates agonist activity at mouse GPRC6A and exhibits inhibition and substrate activity at human LAT1, a transporter involved in amino acid uptake. In terms of enzyme inhibition, it inhibits HDAC6 and exhibits moderate inhibition of CYP3A4. With a high partition coefficient (logP=4.25), it has shown low potential for drug-induced liver injury, making it a safer candidate for therapeutic development. These collective activities suggest that L-Arginine holds promise for various clinical and agricultural applications..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	L-Arginine (L-Arg) is a substrate for endothelial nitric oxide synthase (eNOS), participating in protein synthesis, polyamine production, and cellular signaling regulation. L-Arginine is transported into vascular smooth muscle cells via the cationic amino acid transporter family and metabolized into nitric oxide, polyamines, or L-proline. L-Arginine is an effective vasodilator and can be used to induce experimental acute pancreatitis.
Targets & IC50	L-homoarginine:115.8 μM, HEK293 cells:283 μM (EC50)
In vitro	Methods: Primary human naive CD4+ and CD8+ T cells were cultured with L-Arginine (3-12 mM) for 48 hours. After 4 days, IL-2 was added and the cells were cultured for an additional 3 days. Following this, IL-2 was withdrawn and the cells were cultured further. Annexin V staining and flow cytometry were used to assess survival rates. Results: High L-Arginine significantly increased the survival rate of CD4+ and CD8+ T cells after IL-2 withdrawal. [1] Methods: Adult (8–10 weeks old) WT mouse hippocampal neural stem/progenitor cells (aNPCs) were treated with L-Arginine (100 or 500 μM) concurrently with BrdU labeling for 6–8 hours. BrdU incorporation assays assessed cell proliferation. Results: L-Arginine treatment significantly increased the proliferation rate of WT-aNPCs. [2]
In vivo	Methods: To investigate the effect of L-Arginine on T cell survival, BALB/c mice underwent adoptive transfer of HA-TCR transgenic CD4+ T cells, followed by immunization with HA peptide + CFA. Mice were then administered oral L-Arginine (1.5 mg/g body weight/day). Fifteen days post-immunization, the number of CD44hi donor T cells in draining lymph nodes was quantified by flow cytometry. Results: In arginine-fed mice, donor T cell numbers were threefold higher than in controls. [1] Methods: Nestin-GFP transgenic mice received continuous L-Arginine (100 μM) infusion via microosmotic pump for 7 days. Analysis assessed activation status and cell cycle exit of Nestin-GFP+ radial glial-like cells (RGLs). Results: L-Arginine infusion increased the proportion of activated RGLs and decreased the proportion of RGLs exiting the cell cycle. [2] Methods: To investigate the acute effects of L-Arginine on catecholamine levels, normal rats received intraperitoneal injections of L-Arginine (600 mg/kg). Blood samples were collected 30 minutes post-administration, and plasma levels of epinephrine (AD), norepinephrine (NA), dopamine (DA), and DOPA were measured by high-performance liquid chromatography or fluorescence assay. Results: L-Arginine increased AD, NA, and DOPA levels by approximately 2-fold, while DA increased by 77.5%. [3]
Synonyms	L-Arg, (S)-(+)-Arginine
Disease Modeling Protocol	Gastric ulcer model Modeling Mechanism： L-Arginine, as a substrate of nitric oxide synthase (NOS), can dilate blood vessels in the gastric mucosa, increase blood flow, and at the same time reduce myeloperoxidase (MPO) activity, reduce inflammatory infiltration, and promote ulcer healing. Related Products： L-Arginine (T3S0364) Modeling Method： Experimental Subject： Mice, Swiss Albino mice, Male, 6-8 weeks old, 25-30g Dosage and Administration Route： Indomethacin 18 mg/kg, Oral (single dose, ulcer induction);Resveratrol 10 mg/kg, Oral (starting 6 hours post-ulcer induction, once daily); L-Arginine hydrochloride 25-75 mg/kg, Intraperitoneal injection (administered concurrently with resveratrol, once daily) Dosing Frequency and Duration Model： Indomethacin single dose, resveratrol and L-arginine administered once daily until ulcer healing (maximum 15 days). Validation： The ulcer damage score (DS) decreased, with the L-Arginine 75 mg/kg group showing significant improvement compared to the resveratrol group; MPO activity decreased, and inflammatory cell infiltration was reduced; NO synthesis in gastric tissue increased, and the eNOS/iNOS ratio increased; PGE₂ synthesis gradually recovered, and ulcer mucosal healing was accelerated. Precautions： All mice were sacrificed in batches at 1, 4, 7, and 15 days after modeling, and gastric tissue samples were collected simultaneously. Mice were fasted for 24 hours before indomethacin induction (with free access to water). References：Guha P, et,al. Pro-ulcer effects of resveratrol in mice with indomethacin-induced gastric ulcers are reversed by L-arginine. Br J Pharmacol. 2010 Feb 1;159(3):726-34. Pancreatitis model Modeling Mechanism： L-Arginin is metabolized to produce a large amount of nitric oxide (NO). NO reacts with oxygen free radicals to produce toxic peroxynitrite, which damages pancreatic acinar cells. At the same time, it interferes with the secretion of pancreatic enzymes, leading to pancreatic tissue edema, necrosis and inflammatory infiltration, which in turn indirectly damages the intestinal mucosal barrier and causes intestinal flora imbalance. Related Products： L-Arginine (T3S0364) Modeling Method： Experimental Subject： Mouse, C57BL/6J, Male, 20–22 g, 6–8 weeks old Dosage and Administration Route： 4 g/kg, 10% L-Arginine, dissolved in distilled water and administered intraperitoneally Dosing Frequency and Duration Model： Administered twice at 1-hour intervals Validation： Serum lipase activity was significantly increased, calcium ion concentration was significantly decreased, and pancreatic MPO expression was upregulated; small intestinal villus necrosis, edema, and inflammatory cell infiltration were observed, and Occludin and ZO-1 expression was decreased; the richness and diversity of the gut microbiota decreased, with increased abundance of Bacteroidetes and Proteobacteria and decreased abundance of Firmicutes. Precautions： Seventy-two hours after modeling, the mice were anesthetized and euthanized by cervical dislocation. References：Zhang P,et,al.Comprehensive analysis of intestinal barrier function and microbial diversity changes in L-arginine-induced acute pancreatitis mice. Eur J Med Res. 2025 Sep 29;30(1):912.

Chemical Properties

Molecular Weight	174.20
Formula	C₆H₁₄N₄O₂
Cas No.	74-79-3
Smiles	C(CCNC(=N)N)[C@@H](C(O)=O)N
Relative Density.	Ca. 1.36 - 1.56 g/cm3. Temperature:20 °C.

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: Insoluble

H2O: 104.00 mg/mL (597.01 mM), Sonication is recommended.

Solution Preparation Table

H2O

	1mg	5mg	10mg	50mg
1 mM	5.7405 mL	28.7026 mL	57.4053 mL	287.0264 mL
5 mM	1.1481 mL	5.7405 mL	11.4811 mL	57.4053 mL
10 mM	0.5741 mL	2.8703 mL	5.7405 mL	28.7026 mL
20 mM	0.2870 mL	1.4351 mL	2.8703 mL	14.3513 mL
50 mM	0.1148 mL	0.5741 mL	1.1481 mL	5.7405 mL
100 mM	0.0574 mL	0.2870 mL	0.5741 mL	2.8703 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.